Premium
A novel mutation in the EIF2AK3 gene with variable expressivity in two patients with Wolcott–Rallison syndrome
Author(s) -
Durocher F,
Faure R,
Labrie Y,
Pelletier L,
Bouchard I,
Laframboise R
Publication year - 2006
Publication title -
clinical genetics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.543
H-Index - 102
eISSN - 1399-0004
pISSN - 0009-9163
DOI - 10.1111/j.1399-0004.2006.00632.x
Subject(s) - nonsense mutation , mutation , genetics , medicine , gene , bioinformatics , biology , missense mutation
Mutations in the EIF2AK3 gene have been identified in patients with Wolcott–Rallison syndrome – a rare autosomal recessive disorder associated with permanent neonatal insulin‐dependent diabetes. Despite the fact that different mutations have been observed in every single unrelated case reported so far, most patients presented with similar characteristics, such as osteopenia, epiphyseal dysplasia as well as hepatic and/or renal dysfunction. The EIF2AK3 gene was analyzed using a PCR‐based sequencing approach in two Wolcott–Rallison patients and their parents. We report two cases from different families carrying the same and novel truncating nonsense mutation in the EIF2AK3 gene that encodes the pancreatic eukaryotic initiation factor 2α kinase 3. This mutation clearly displays different clinical characteristics in the two patients we examined. Remarkably, the onset of diabetes was different for the two patients, and there was also heterogeneity in other clinical manifestations. These cases illustrate the important role of alternative pathways that could, to some extent, take over or supplement a defective metabolic pathway. This supports the idea that there is no simple relationship among clinical manifestations and EIF2AK3 mutations.